ID   PRIO_HUMAN     STANDARD;      PRT;   253 AA.
AC   P04156;
DT   01-NOV-1986 (REL. 03, CREATED)
DT   01-NOV-1986 (REL. 03, LAST SEQUENCE UPDATE)
DT   01-NOV-1997 (REL. 35, LAST ANNOTATION UPDATE)
DE   MAJOR PRION PROTEIN PRECURSOR (PRP) (PRP27-30) (PRP33-35C) (ASCR).
GN   PRNP.
OS   HOMO SAPIENS (HUMAN).
OC   EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; TETRAPODA; MAMMALIA;
OC   EUTHERIA; PRIMATES.
RN   [1]
RP   SEQUENCE FROM N.A.
RX   MEDLINE; 86300093.
RA   KRETZSCHMAR H.A., STOWRING L.E., WESTAWAY D., STUBBLEBINE W.H.,
RA   PRUSINER S.B., DEARMOND S.J.;
RL   DNA 5:315-324(1986).
RN   [2]
RP   SEQUENCE OF 8-253 FROM N.A.
RX   MEDLINE; 86261778.
RA   LIAO Y.-C.J., LEBO R.V., CLAWSON G.A., SMUCKLER E.A.;
RL   SCIENCE 233:364-367(1986).
RN   [3]
RP   VARIANT AMYLOID GSS, SEQUENCE OF 58-85 AND 111-150.
RX   MEDLINE; 91160504.
RA   TAGLIAVINI F., PRELLI F., GHISO J., BUGIANI O., SERBAN D.,
RA   PRUSINER S.B., FARLOW M.R., GHETTI B., FRANGIONE B.;
RL   EMBO J. 10:513-519(1991).
RN   [4]
RP   REVIEW ON VARIANTS.
RX   MEDLINE; 93372867.
RA   PALMER M.S., COLLINGE J.;
RL   HUM. MUTAT. 2:168-173(1993).
RN   [5]
RP   REVIEW ON VARIANTS.
RX   MEDLINE; 94029646.
RA   PRUSINER S.B.;
RL   ARCH. NEUROL. 50:1129-1153(1993).
RN   [6]
RP   VARIANT GSS LEU-102.
RX   MEDLINE; 89159432.
RA   HSIAO K., BAKER H.F., CROW T.J., POULTER M., OWEN F.,
RA   TERWILLIGER J.D., WESTAWAY D., OTT J., PURSINER S.B.;
RL   NATURE 338:342-345(1989).
RN   [7]
RP   VARIANTS LEU-102; VAL-117 AND VAL-129.
RX   MEDLINE; 89392018.
RA   DOH-URA K., TATEISHI J., SASAKI H., KITAMOTO T., SAKAKI Y.;
RL   BIOCHEM. BIOPHYS. RES. COMMUN. 163:974-979(1989).
RN   [8]
RP   VARIANT FFI ASN-178.
RX   MEDLINE; 92195483.
RA   MEDORI R., MONTAGNA P., TRITSCHLER H.J., LEBLANC A., CORTELLI P.,
RA   TINUPER P., LUGARESI E., GAMBETTI P.;
RL   NEUROLOGY 42:669-670(1992).
RN   [9]
RP   VARIANT CJD ASN-178.
RX   MEDLINE; 91124933.
RA   GOLDFARB L.G., HALTIA M., BROWN P., NIETO A., KOVANEN J.,
RA   MCCOMBIE W.R., TRAPP S., GAJDUSEK D.C.;
RL   LANCET 337:425-425(1991).
RN   [10]
RP   VARIANT CJD LYS-200.
RX   MEDLINE; 90355709.
RA   GOLDFARB L., MITROVA E., BROWN P., TOH B.K., GAJDUSEK D.C.;
RL   LANCET 336:514-515(1990).
RN   [11]
RP   VARIANT GSS ARG-217.
RX   MEDLINE; 93250977.
RA   HSIAO K., DLOUHY S.R., FARLOW M.R., CASS C., DA COSTA M.,
RA   CONNEALLY P.M., HODES M.E., GHETTI B., PRUSINER S.B.;
RL   NAT. GENET. 1:68-71(1992).
RN   [12]
RP   VARIANTS CJD ILE-180 AND ARG-223.
RX   MEDLINE; 93213314.
RA   KITAMOTO T., OHTA M., DOH-URA K., HITOSHI S., TERAO Y., TATEISHI J.;
RL   BIOCHEM. BIOPHYS. RES. COMMUN. 191:709-714(1993).
RN   [13]
RP   VARIANT CJD ILE-210.
RX   MEDLINE; 94071412.
RA   POCCHIARI M., SALVATORE M., CUTRUZZOLA F., GENUARDI M.,
RA   ALLCATELLI C.T., MASULLO C., MACCHI G., ALEMA G., GALGANI S., XI Y.G.,
RA   PETRAROLI R., SILVESTRINI M.C., BRUNORI M.;
RL   ANN. NEUROL. 34:802-807(1993).
RN   [14]
RP   VARIANT GSS LEU-105.
RX   MEDLINE; 94077414.
RA   YAMADA M., ITOH Y., FUJIGASAKI H., NARUSE S., KANEKO K., KITAMOTO T.,
RA   TATEISHI J., OTOMO E., HAYAKAWA M., TANAKA J., MATSUSHITA M.,
RA   MIYATAKE T.;
RL   NEUROLOGY 43:2723-2724(1993).
RN   [15]
RP   VARIANT GSS LEU-105.
RX   MEDLINE; 95213742.
RA   ITOH Y., YAMADA M., HAYAKAWA M., SHOZAWA T., TANAKA J., MATSUSHITA M.,
RA   KITAMOTO T., TATEISHI J., OTOMO E.;
RL   J. NEUROL. SCI. 127:77-86(1994).
RN   [16]
RP   VARIANT CJD LYS-200.
RX   MEDLINE; 94142912.
RA   INOUE I., KITAMOTO T., DOH-URA K., SHII H., GOTO I., TATEISHI J.;
RL   NEUROLOGY 44:299-301(1994).
RN   [17]
RP   VARIANT CJD LYS-200.
RX   MEDLINE; 94316708.
RA   GABIZON R., ROSENMAN H., MEINER Z., KAHANA I., KAHANA E., SHUGART Y.,
RA   OTT J., PRUSINER S.B.;
RL   PHILOS. TRANS. R. SOC. LOND., B, BIOL. SCI. 343:385-390(1994).
RN   [18]
RP   VARIANT GSS LEU-102.
RX   MEDLINE; 95303274.
RA   YOUNG K., JONES C.K., PICCARDO P., LAZZARINI A., GOLBE L.I.,
RA   ZIMMERMAN T.R., DICKSON D.W., MCLACHLAN D.C., ST GEORGE-HYSLOP P.,
RA   LENNOX A.;
RL   NEUROLOGY 45:1127-1134(1995).
CC   -!- FUNCTION: THE FUNCTION OF PRP IS NOT KNOWN. PRP IS ENCODED IN THE
CC       HOST GENOME AND IS EXPRESSED BOTH IN NORMAL AND INFECTED CELLS.
CC   -!- SUBUNIT: PRP HAS A TENDENCY TO AGGREGATE YIELDING POLYMERS CALLED
CC       "RODS".
CC   -!- SUBCELLULAR LOCATION: ATTACHED TO THE MEMBRANE BY A GPI-ANCHOR.
CC   -!- DISEASE: PRP IS FOUND IN HIGH QUANTITY IN THE BRAIN OF HUMANS AND
CC       ANIMALS INFECTED WITH NEURODEGENERATIVE DISEASES KNOWN AS
CC       TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES OR PRION DISEASES, LIKE:
CC       CREUTZFELDT-JACOB DISEASE (CJD), GERSTMANN-STRAUSSLER SYNDROME
CC       (GSS), FATAL FAMILIAL INSOMNIA (FFI) AND KURU IN HUMANS; SCRAPIE
CC       IN SHEEP AND GOAT; BOVINE SPONGIFORM ENCEPHALOPATHY (BSE) IN
CC       CATTLE; TRANSMISSIBLE MINK ENCEPHALOPATHY (TME); CHRONIC WASTING
CC       DISEASE (CWD) OF MULE DEER AND ELK; FELINE SPONGIFORM
CC       ENCEPHALOPATHY (FSE) IN CATS AND EXOTIC UNGULATE ENCEPHALOPATHY
CC       (EUE) IN NYALA AND GREATER KUDU. THE PRION DISEASES ILLUSTRATE
CC       THREE MANIFESTATIONS OF CNS DEGENERATION: (1) INFECTIOUS (2)
CC       SPORADIC AND (3) DOMINANTLY INHERITED FORMS. TME, CWD, BSE, FSE,
CC       EUE ARE ALL THOUGHT TO OCCUR AFTER CONSUMPTION OF PRION-INFECTED
CC       FOODSTUFFS.
CC   -!- DISEASE: CJD OCCURS PRIMARILY AS A SPORADIC DISORDER (1 PER
CC       MILLION), WHILE 10-15% ARE FAMILIAL. ACCIDENTAL TRANSMISSION OF
CC       CJD TO HUMANS APPEARS TO BE IATROGENIC (CONTAMINATED HUMAN GROWTH
CC       HORMONE (HGH), CORNEAL TRANSPLANTATION, ELECTROENCEPHALOGRAPHIC
CC       ELECTRODE IMPLANTATION. . .). EPIDEMIOLOGIC STUDIES HAVE FAILED TO
CC       IMPLICATE THE INGESTION OF INFECTED ANNIMAL MEAT IN THE
CC       PATHOGENESIS OF CJD IN HUMAN. THE TRIAD OF MICROSCOPIC FEATURES
CC       THAT CHARACTERIZE THE PRION DISEASES CONSISTS OF (1) SPONGIFORM
CC       DEGENERATION OF NEURONS, (2) SEVERE ASTROCYTIC GLIOSIS THAT OFTEN
CC       APPEARS TO BE OUT OF PROPORTION TO THE DEGREE OF NERF CELL LOSS,
CC       AND (3) AMYLOID PLAQUE FORMATION. CJD IS CHARACTERIZED BY
CC       PROGRESSIVE DEMENTIA AND MYOCLONIC SEIZURES, AFFECTING ADULTS IN
CC       MID-LIFE. SOME PATIENTS PRESENT SLEEP DISORDERS, ABNORMALITIES OF
CC       HIGH CORTICAL FUNCTION, CEREBELLAR AND CORTICOSPINAL DISTURBANCES.
CC       THE DISEASE ENDS IN DEATH AFTER A 3-12 MONTHS ILLNESS.
CC   -!- DISEASE: GSS IS A HETEROGENEOUS DISORDER AND WAS DEFINED AS A
CC       "SPINOCEREBELLAR ATAXIA WITH DEMENTIA AND PLAQUELIKE DEPOSITS".
CC       GSS INCIDENCE IS LESS THAN 2 PER 100 MILLION.
CC   -!- DISEASE: KURU IS TRANSMITTED DURING RITUALISTIC CANNIBALISM, AMONG
CC       NATIVES OF THE NEW GUINEA HIGHLANDS. PATIENTS EXHIBIT VARIOUS
CC       MOVEMENT DISORDERS LIKE CEREBELLAR ABNORMALITIES, RIGIDITY OF THE
CC       LIMBS, AND CLONUS. EMOTIONNAL LABILITY IS PRESENT, AND DEMENTIA IS
CC       CONSPICUOUSLY ABSENT. DEATH USUALLY OCCURS FROM 3 TO 12 MONTH
CC       AFTER ONSET.
CC   -!- SIMILARITY: TO OTHER PRP.
CC   -!- DATABASE: NAME=HotMolecBase; NOTE=PrP entry;
CC       WWW="http://bioinformatics.weizmann.ac.il/hotmolecbase/entries/prp.htm".
DR   EMBL; M13667; G190470; -.
DR   EMBL; M13899; G190468; -.
DR   EMBL; D00015; G220016; -.
DR   PIR; A05017; A05017.
DR   PIR; A24173; A24173.
DR   PIR; S14078; S14078.
DR   MIM; 176640; -.
DR   MIM; 123400; -.
DR   MIM; 137440; -.
DR   MIM; 245300; -.
DR   MIM; 600072; -.
DR   PROSITE; PS00291; PRION_1; 1.
DR   PROSITE; PS00706; PRION_2; 1.
KW   PRION; BRAIN; GLYCOPROTEIN; GPI-ANCHOR; REPEAT; SIGNAL;
KW   POLYMORPHISM; DISEASE MUTATION.
FT   SIGNAL        1     22
FT   CHAIN        23    230       MAJOR PRION PROTEIN.
FT   PROPEP      231    253       REMOVED IN MATURE FORM (BY SIMILARITY).
FT   LIPID       230    230       GPI-ANCHOR (BY SIMILARITY).
FT   CARBOHYD    181    181       PROBABLE.
FT   CARBOHYD    197    197       PROBABLE.
FT   DISULFID    179    214       BY SIMILARITY.
FT   DOMAIN       51     91       5 X 8 AA TANDEM REPEATS OF P-H-G-G-G-W-G-
FT                                Q.
FT   REPEAT       51     59       1.
FT   REPEAT       60     67       2.
FT   REPEAT       68     75       3.
FT   REPEAT       76     83       4.
FT   REPEAT       84     91       5.
FT   VARIANT     102    102       P -> L (IN GSS).
FT   VARIANT     105    105       P -> L (IN GSS).
FT   VARIANT     117    117       A -> V (LINKED TO DEVELOPMENT OF
FT                                DEMENTING GSS).
FT   VARIANT     129    129       M -> V (DETERMINES THE DISEASE PHENOTYPE
FT                                IN PATIENTS WHO HAVE A PRP MUTATION AT
FT                                CODON 178: PATIENTS WITH MET DEVELOP FFI,
FT                                THOSE WITH VAL DEVELOP CJD).
FT   VARIANT     178    178       D -> N (IN FFI AND CJD).
FT   VARIANT     180    180       V -> I (IN CJD).
FT   VARIANT     198    198       F -> S (IN A ATYPICAL FORM OF GSS WITH
FT                                NEUROFIBRILLARY TANGLES).
FT   VARIANT     200    200       E -> K (IN CJD).
FT   VARIANT     210    210       V -> I (IN CJD).
FT   VARIANT     217    217       Q -> R (IN GSS WITH NEUROFIBRILLARY
FT                                TANGLES).
FT   VARIANT     232    232       M -> R (IN CJD).
FT   CONFLICT    118    118       MISSING (IN REF. 2).
SQ   SEQUENCE   253 AA;  27661 MW;  FD5373AD CRC32;
     MANLGCWMLV LFVATWSDLG LCKKRPKPGG WNTGGSRYPG QGSPGGNRYP PQGGGGWGQP
     HGGGWGQPHG GGWGQPHGGG WGQPHGGGWG QGGGTHSQWN KPSKPKTNMK HMAGAAAAGA
     VVGGLGGYML GSAMSRPIIH FGSDYEDRYY RENMHRYPNQ VYYRPMDEYS NQNNFVHDCV
     NITIKQHTVT TTTKGENFTE TDVKMMERVV EQMCITQYER ESQAYYQRGS SMVLFSSPPV
     ILLISFLIFL IVG
//
